DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hereditary Angioedema Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Hereditary Angioedema market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hereditary Angioedema: An Overview
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx
HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.
Hereditary Angioedema Market Key Facts
-
The total diagnosed prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.
-
Among the European countries, France had the highest Hereditary Angioedema prevalent population of 1,346 cases, followed by the UK which had a prevalent population of 1,301 in 2017.
-
Spain had the lowest Hereditary Angioedema prevalent population among the EU5 countries, with 537 cases in 2017.
-
Hereditary Angioedema in the US has been observed with the maximum number of diagnosed cases in the age-group 17 to below 65 years, followed by those who belong to the age-group 12 to less than 17 years.
-
According to DelveInsight’s analysis, Hereditary Angioedema is more prominent in females than males.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Hereditary Angioedema market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Hereditary Angioedema market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Hereditary Angioedema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Hereditary Angioedema Epidemiology Segmentation
-
Total Diagnosed Prevalent cases of Hereditary Angioedema
-
Gender-specific cases of Hereditary Angioedema
-
Site-specific cases of Hereditary Angioedema
-
Type-specific cases of Hereditary Angioedema
-
Age-specific cases of Hereditary Angioedema
Hereditary Angioedema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched during the study period. The analysis covers Hereditary Angioedema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hereditary Angioedema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report - https://www.delveinsight.com/sample-request/hereditary-angioedema-market
Hereditary Angioedema Therapeutics Analysis
Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow Hereditary Angioedema patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies.
Some of the key companies in the Hereditary Angioedema Market include:
-
CSL Behring
-
Takeda
-
Shire
-
Pharming Group
-
BioCryst Pharmaceuticals
-
Ionis Pharmaceuticals
-
KalVista Pharmaceuticals
And many others
Hereditary Angioedema Therapies covered in the report include:
-
KVD900
-
CSL312
-
Takhzyro
-
Firazyr
-
Ruconest
-
BCX7353
-
Berinert
-
Haegarda
-
Kalbitor
-
Cinryze
-
IONIS-PKK-LRx
And many more
Get More Detailed Insights Into the Emerging Therapies & Key Companies -
https://www.delveinsight.com/sample-request/hereditary-angioedema-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hereditary Angioedema Competitive Intelligence Analysis
4. Hereditary Angioedema Market Overview at a Glance
5. Hereditary Angioedema Disease Background and Overview
6. Hereditary Angioedema Patient Journey
7. Hereditary Angioedema Epidemiology and Patient Population
8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices
9. Hereditary Angioedema Unmet Needs
10. Key Endpoints of Hereditary Angioedema Treatment
11. Hereditary Angioedema Marketed Products
12. Hereditary Angioedema Emerging Therapies
13. Hereditary Angioedema Seven Major Market Analysis
14. Attribute Analysis
15. Hereditary Angioedema Market Outlook (7 major markets)
16. Hereditary Angioedema Access and Reimbursement Overview
17. KOL Views on the Hereditary Angioedema Market.
18. Hereditary Angioedema Market Drivers
19. Hereditary Angioedema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report - https://www.delveinsight.com/sample-request/hereditary-angioedema-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Artificial Cornea and Corneal Implant Market
“Artificial Cornea and Corneal Implant Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for the Artificial Cornea and Corneal Implant. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Artificial Cornea and Corneal Implant market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
